5-((3-bromopyridin-4-yl)methoxy)-2-chloropyrimidine | 1272974-29-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-((3-bromopyridin-4-yl)methoxy)-2-chloropyrimidine
• 英文别名: 5-[(3-Bromopyridin-4-yl)methoxy]-2-chloropyrimidine
• CAS: 1272974-29-4
• 化学式: C₁₀H₇BrClN₃O
• 分子量: 300.542
• InChiKey: WVBMMUZYBJITFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  47.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-((3-bromopyridin-4-yl)methoxy)-2-chloropyrimidine 在 盐酸 、 碳酸氢钠 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 13.0h， 生成 3-(5-((3-bromopyridin-4-yl)methoxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carbonitrile
  参考文献：
  名称：

  Conformational restriction in a series of GPR119 agonists: Differences in pharmacology between mouse and human

  摘要：

  A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.006
• 作为产物：
  描述：

  3-溴吡啶-4-甲醇 、 2-氯-5-羟基嘧啶 在 甲基磺酰氯 、 N,N-二异丙基乙胺 、 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 以69%的产率得到5-((3-bromopyridin-4-yl)methoxy)-2-chloropyrimidine
  参考文献：
  名称：

  Therapeutic Agents 812

  摘要：

  公式I的化合物或其药用可接受的盐，制备这类化合物的方法，它们作为GPR119调节剂的用途，它们的治疗用途的方法，特别是在肥胖和糖尿病的治疗中，以及含有它们的药物组合物。

  公开号：

  US20110065706A1

文献信息

• [EN] 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS<br/>[FR] DERIVES DE 4-(PYRIMIDIN-2-YL)-PIPERAZINE ET DE 4-(PYRIMIDIN-2-YL)-PIPERIDINE UTILISES EN TANT QUE MODULATEURS DU GPR119
  申请人：ASTRAZENECA AB

  公开号：WO2011030139A1

  公开（公告）日：2011-03-17

  A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as GPR119 modulators, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus, and pharmaceutical compositions containing them.
• Therapeutic Agents 812
  申请人：Birch Alan Martin

  公开号：US20110065706A1

  公开（公告）日：2011-03-17

  A compound of formula I or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as GPR119 modulators, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus, and pharmaceutical compositions containing them.

  公式I的化合物或其药用可接受的盐，制备这类化合物的方法，它们作为GPR119调节剂的用途，它们的治疗用途的方法，特别是在肥胖和糖尿病的治疗中，以及含有它们的药物组合物。
• Conformational restriction in a series of GPR119 agonists: Differences in pharmacology between mouse and human
  作者：James S. Scott、Katy J. Brocklehurst、Hayley S. Brown、David S. Clarke、Helen Coe、Sam D. Groombridge、David Laber、Philip A. MacFaul、Darren McKerrecher、Paul Schofield

  DOI：10.1016/j.bmcl.2013.04.006

  日期：2013.6

  A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors. (C) 2013 Elsevier Ltd. All rights reserved.